Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. - Wikidata - wikimedia - TriplyDB

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

http://www.wikidata.org/entity/Q33898869

about

Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics What is the Need for Prostatic Biomarkers in Prostate Cancer Management?Prostate cancer biomarkers: Are we hitting the mark?How Precisely Can Prostate Cancer Be Managed?Prognostic outlier genes for enhanced prostate cancer treatment.Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.RNA biomarkers to facilitate the identification of aggressive prostate cancer Prostatic compensation of the vitamin D axis in African American men.An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis Clinically available RNA profiling tests of prostate tumors: utility and comparison High Dimensional Variable Selection with Error Control Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.Prediction of prostate cancer recurrence using quantitative phase imaging: Validation on a general population Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.Biomarkers for prostate cancer: present challenges and future opportunities.Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.

P2860

Q24289356-3F53F7DB-A611-497F-9D0F-6FDCA422F8EB Q26750672-FB4B9F20-E1E0-4F44-A39B-D0B1FA4635F4 Q26752510-7434C0B8-974F-4EB5-954B-0D97DBFABA1A Q26798425-AE38B66B-F677-41DF-BA23-6636E9214EE6 Q28071654-C5EF2AC4-F178-4DC0-A59E-96B5889565DA Q28078942-1ABE09C5-E28F-4F03-ACFE-DDCC73C9064B Q30244674-994A24A7-FD2A-4FDE-872B-468BB6C2184F Q30276626-E356B955-B6FF-4535-8904-B72905D277B5 Q30371634-A93BC312-7C50-4A63-B23E-52FFB8C5405D Q30405851-35BCE09E-9F55-4F33-AB16-B3C7E2166DFB Q30938412-7765BB98-B3E2-40F1-8AD4-A8A4A5F971FF Q33696684-D73548B1-B055-443B-B2B8-CE78A9288E36 Q33701564-2755171E-EB2E-47C0-B003-D9E7FBBAC15C Q33793232-86C128C6-1F78-43FC-A03D-F307C6D44D48 Q34550412-BF8E046B-A7B4-4DE5-BDAE-638A8B6A81E8 Q34807402-63B0CA6D-96BA-40AD-95CF-954FA9EFE5DB Q35096149-85734359-F093-4B7B-9902-5082E009759E Q35211723-7629A84E-3EC0-4215-AA20-CAD9F7C413EF Q35868145-82A68CDD-4B41-4842-85BE-2F4F462D2D4E Q35873154-D268A603-A2E7-48B9-8BB6-3468310CA4C9 Q36025180-4164964C-C831-4CBF-9C78-2F2265E8D1E2 Q36035812-6117C6CD-5E35-4230-B1C1-2C4739FBD930 Q36172537-97D464C6-0DDE-4237-967F-D65C792B09C4 Q36260364-80B7429B-CDFA-4AED-A0F9-EC685F0B5F25 Q36264367-F2F7E774-5439-4E85-B814-3CE046458C05 Q36286694-E19FDB31-2A75-468E-88CA-0E7DBD1603E3 Q36314809-F2F9EF49-BA1E-47EE-B97A-BEC77A67BD22 Q36471474-154E7D28-7A57-403F-AD52-A4811062AA6B Q36945088-BC830A67-9195-492D-A868-591911B58BE7 Q37029385-3F514ED5-1799-4748-BB1A-633E2B6D7743 Q37038406-F7FEEE96-A0D4-4646-A3E2-5AA6E32F8095 Q37070927-827FEC29-8046-4FE8-90C7-65F01956E1CA Q37113181-014B9646-2881-4AC7-AAB3-DF0389F08D98 Q37212655-4FD0D0AB-5382-44EC-8020-3722D48B6E87 Q37269294-1BCEFB4C-A663-4AB7-B39B-5913B5C7FBD8 Q37278199-80CD3742-77D1-4CC0-A6FB-FC1F1E96B54D Q37463713-59DE3E05-F17F-49FD-A413-F91198097BBA Q37474443-627C939A-C6BF-49B9-98B4-552EA4761010 Q37619763-3C98B1D3-E3D6-4FE4-909D-7B0B20025D06 Q37629548-F775E983-1D7E-4584-85EC-D5473CF4A20C

P2860

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

http://www.wikidata.org/entity/Q33898869

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Validation of a genomic classi ...... an at risk patient population.

@ast

Validation of a genomic classi ...... an at risk patient population.

@en

type

label

Validation of a genomic classi ...... an at risk patient population.

@ast

Validation of a genomic classi ...... an at risk patient population.

@en

prefLabel

Validation of a genomic classi ...... an at risk patient population.

@ast

Validation of a genomic classi ...... an at risk patient population.

@en

P1433

Q33898869-F5DD5FA8-BC4C-4458-9C6B-3610337A9776

P1476

Q33898869-CDD5F6DA-050F-45A7-9221-EA2F22D73B27

P2093

Q33898869-136E2EB6-9657-4079-A89A-40158359D3A9

Q33898869-15BD3CB6-2210-4430-B6B3-39E6420EC98F

Q33898869-17D4BF61-D060-4A3F-85E1-36C70143CA57

Q33898869-3BE0D94E-E8F3-4452-8CDE-3FDFB2CA87F1

Q33898869-40D1837A-0BF9-4865-AED6-A2334530D07F

Q33898869-6CFAEE28-59B0-42C6-97AD-08D723A4450F

Q33898869-85579C31-249B-4EA0-95DE-8250D991A1B3

Q33898869-8B8263C9-437C-441B-8244-8F65118BEF39

Q33898869-8CD6FE7A-6871-4EA0-9747-CC6DD039D485

Q33898869-A87EE988-0432-48FB-9FFB-7EBFC4B63C1D

P2860

Q33898869-01DDABB3-3002-43A9-AF59-93EE7962EEEC

Q33898869-04886BC6-D5C2-4C52-AD7F-DE4A4E771402

Q33898869-09D8816C-DE70-4E23-AC5B-2469E50B6A3B

Q33898869-111819E2-B11A-4647-9EBF-D444354A94B6

Q33898869-1839328A-B7CC-4ADD-88E1-FF7EF4618A3D

Q33898869-43579E83-1E8A-4A2F-B25F-353D3ED89933

Q33898869-533784D5-37AC-484A-964D-1825240475E3

Q33898869-57A3FF4A-101B-45CB-B12D-D1971AE14788

Q33898869-65855CBC-6597-4EBB-A6F7-D9DE1C071294

Q33898869-6E4C08A6-A1B9-4356-B821-D555C08F01A5

P304

Q33898869-B5087965-0370-410D-89CA-E4835683320B

P31

Q33898869-B794EED9-3A11-4A29-BA08-85375E36DFDB

P356

Q33898869-28EFB204-6732-492E-8E53-ED727ABC44E0

P407

Q33898869-B9D200AF-9D9E-487E-851E-150E4C664344

P433

Q33898869-C27C7CA9-DC2C-4247-A048-2121468DD3BD

P478

Q33898869-798196B2-24CD-469D-B80D-FA0F62970F5C

P50

Q33898869-0EB7974C-B0DF-4B28-8010-EA9586CF81CD

Q33898869-31098B76-16DB-4726-B0B5-50950A3CFA0F

Q33898869-7A297BFC-65E2-43B0-906A-A4519A1820B8

Q33898869-983ED263-B236-45B6-A1D0-73D75033F5A8

Q33898869-D78BBE87-4250-4B37-B613-CCC162691C7C

P577

Q33898869-B8E2E090-C2D9-4EDF-8394-51E889BC7DC0

P698

Q33898869-F5E55E41-FF4A-44F9-9599-36557E85001D

P921

Q33898869-EC7850E6-A1B9-40CC-AF5E-FA647D4F6AFD

P932

Q33898869-822A857C-9398-4095-B048-ED6BC08FC6DC

P356

J.JURO.2013.06.017

P1433

The Journal of Urology

P1476

Validation of a genomic classi ...... an at risk patient population

@en

P2093

Anamaria Crisan

http://www.w3.org/2001/XMLSchema#string

Benedikt Zimmermann

http://www.w3.org/2001/XMLSchema#string

Christine Buerki

http://www.w3.org/2001/XMLSchema#string

Darby J S Thompson

http://www.w3.org/2001/XMLSchema#string

Eric J Bergstralh

http://www.w3.org/2001/XMLSchema#string

George G Klee

http://www.w3.org/2001/XMLSchema#string

Ismael A Vergara

http://www.w3.org/2001/XMLSchema#string

Lucia L Lam

http://www.w3.org/2001/XMLSchema#string

Mercedeh Ghadessi

http://www.w3.org/2001/XMLSchema#string

Peter C Black

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

Cancer statistics, 2012

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

Natural history of progression after PSA elevation following radical prostatectomy.

Impact of biochemical recurrence in prostate cancer among US veterans.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression

The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.

Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.

P304

2047-2053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2013.06.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

190

http://www.w3.org/2001/XMLSchema#string

P50

Karla V Ballman

Anirban P Mitra

P577

2013-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23770138

http://www.w3.org/2001/XMLSchema#string

P921

P932

4097302

http://www.w3.org/2001/XMLSchema#string